NORTH CHICAGO, Ill. and MECHELEN, Belgium, Sept. 24, 2013 /PRNewswire/ -- Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today that they have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide.
GHENT, Belgium and NORTH CHICAGO, Ill., Sept. 23, 2013 /PRNewswire/ -- Ablynx [Euronext Brussels: ABLX] and AbbVie [NYSE: ABBV] today announced that they have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases. ALX-0061 is Ablynx's proprietary anti-IL-6R Nanobody that successfully completed a Phase IIa study in February 2013 reporting strong efficacy and safety data in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.
NORTH CHICAGO, Ill., Aug. 19, 2013 /PRNewswire/ -- AbbVie has selected 40 exceptional undergraduate and graduate students living with cystic fibrosis (CF) to each receive a $2,500 AbbVie CF Scholarship for the 2013-2014 school year based on their academic excellence, extracurricular activities and creativity. The AbbVie CF Scholars are now competing for two additional scholarships for a total award of $21,000 each and the title of 2013 Thriving Undergraduate or Graduate Student. From now until Monday, Sept. 16, 2013, please vote at www.AbbVieCFScholarship.com for two outstanding and inspirational scholars.
NORTH CHICAGO, Ill., July 26, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced financial results for the second quarter ended June 30, 2013.
NORTH CHICAGO, Ill., July 8, 2013 /PRNewswire/ -- Stacy London, style expert and co-host of TLC's "What Not to Wear," today announced her partnership with AbbVie (NYSE: ABBV) on a new psoriasis campaign called Uncover Your Confidence. The campaign features educational resources and style advice for the estimated 7.5 million American men and women living with psoriasis.[1] Commonly mistaken as "just a skin condition," psoriasis is actually a chronic disease of the immune system that appears on the skin.
NORTH CHICAGO, Ill., June 17, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced preliminary results from a Phase I study of ABT-199/GDC-0199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, in patients with high-risk relapsed/refractory chronic lymphocytic leukemia (CLL), and in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). High-risk CLL patients are those with deletions of chromosome 17p or whose disease is refractory to fludarabine therapy. These data were presented at the 18th Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
MADRID, June 13, 2013 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate (MTX) in combination with HUMIRA® (adalimumab) for the treatment of moderate to severe rheumatoid arthritis (RA). CONCERTO shows that at week 26 of treatment, a statistically significant increasing trend was observed in the proportion of patients achieving low disease activity with an increasing dose of MTX when used with open-label HUMIRA®. Results were presented at the European League Against Rheumatism (EULAR) 2013 Congress in Madrid, Spain.
NORTH CHICAGO, Ill., June 5, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 34th Annual Goldman Sachs Global Healthcare Conference on Thursday, June 13, 2013. Bill Chase, executive vice president and chief financial officer, and Scott Brun, M.D., vice president, pharmaceutical development, will take part in a question and answer session at 12:40 p.m. Central time.
NORTH CHICAGO, Ill., June 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL), the most common leukemia in the United States, and relapsed/refractory non-Hodgkin's lymphoma (NHL). Results from the study were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO).
NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON® (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration (FDA) recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions. This new strength is the highest dose of pancreatic enzyme replacement therapy (PERT) currently available and approved by the FDA.
Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact.
Stay up to date on recent news, articles, and more by subscribing to e-mail alerts for one or more of our news topics.
Receive alerts on new stories, articles, and more by subscribing to one or more RSS Feeds.
YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE
Notice
The "Yes" link below will take you out of the AbbVie family of websites.
Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.
The Internet site that you have requested may not be optimized to your screen size.
Do you wish to leave this site?
